Annual CFF
$88.33 M
+$88.16 M+53758.54%
31 December 2023
Summary:
Aligos Therapeutics annual cash flow from financing activities is currently $88.33 million, with the most recent change of +$88.16 million (+53758.54%) on 31 December 2023. During the last 3 years, it has fallen by -$104.02 million (-54.08%). ALGS annual CFF is now -54.08% below its all-time high of $192.35 million, reached on 31 December 2020.ALGS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$4000.00
-$285.00 K-101.42%
30 September 2024
Summary:
Aligos Therapeutics quarterly cash flow from financing activities is currently -$4000.00, with the most recent change of -$285.00 thousand (-101.42%) on 30 September 2024. Over the past year, it has increased by +$17.00 thousand (+80.95%). ALGS quarterly CFF is now -100.00% below its all-time high of $193.32 million, reached on 31 December 2020.ALGS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$88.19 M
+$17.00 K+0.02%
30 September 2024
Summary:
Aligos Therapeutics TTM cash flow from financing activities is currently $88.19 million, with the most recent change of +$17.00 thousand (+0.02%) on 30 September 2024. Over the past year, it has increased by +$87.68 million (+17091.81%). ALGS TTM CFF is now -67.51% below its all-time high of $271.44 million, reached on 30 September 2021.ALGS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALGS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +81.0% | +10000.0% |
| 3 y3 years | -54.1% | -100.0% | -67.5% |
| 5 y5 years | - | - | - |
ALGS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -54.1% | >+9999.0% | -100.0% | +81.0% | -67.5% | >+9999.0% |
| 5 y | 5 years | -54.1% | >+9999.0% | -100.0% | +99.6% | -67.5% | +9192.2% |
| alltime | all time | -54.1% | >+9999.0% | -100.0% | +99.6% | -67.5% | +9192.2% |
Aligos Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4000.00(-101.4%) | $88.19 M(+0.0%) |
| June 2024 | - | $281.00 K(-1578.9%) | $88.18 M(-0.2%) |
| Mar 2024 | - | -$19.00 K(-100.0%) | $88.31 M(-0.0%) |
| Dec 2023 | $88.33 M(>+9900.0%) | $87.94 M(<-9900.0%) | $88.33 M(>+9900.0%) |
| Sept 2023 | - | -$21.00 K(-105.1%) | $513.00 K(-0.4%) |
| June 2023 | - | $414.00 K(<-9900.0%) | $515.00 K(+179.9%) |
| Mar 2023 | - | -$1000.00(-100.8%) | $184.00 K(+12.2%) |
| Dec 2022 | $164.00 K | $121.00 K(-736.8%) | $164.00 K(-72.4%) |
| Sept 2022 | - | -$19.00 K(-122.9%) | $595.00 K(-99.2%) |
| June 2022 | - | $83.00 K(-495.2%) | $78.57 M(-0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$21.00 K(-103.8%) | $78.58 M(-0.1%) |
| Dec 2021 | $78.68 M(-59.1%) | $552.00 K(-99.3%) | $78.68 M(-71.0%) |
| Sept 2021 | - | $77.95 M(>+9900.0%) | $271.44 M(+41.0%) |
| June 2021 | - | $95.00 K(+21.8%) | $192.54 M(+0.0%) |
| Mar 2021 | - | $78.00 K(-100.0%) | $192.47 M(+0.1%) |
| Dec 2020 | $192.35 M(+124.9%) | $193.32 M(<-9900.0%) | $192.35 M(<-9900.0%) |
| Sept 2020 | - | -$949.00 K(-3614.8%) | -$970.00 K(+4519.0%) |
| June 2020 | - | $27.00 K(-156.3%) | -$21.00 K(-56.3%) |
| Mar 2020 | - | -$48.00 K | -$48.00 K |
| Dec 2019 | $85.53 M | - | - |
FAQ
- What is Aligos Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aligos Therapeutics?
- What is Aligos Therapeutics annual CFF year-on-year change?
- What is Aligos Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aligos Therapeutics?
- What is Aligos Therapeutics quarterly CFF year-on-year change?
- What is Aligos Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aligos Therapeutics?
- What is Aligos Therapeutics TTM CFF year-on-year change?
What is Aligos Therapeutics annual cash flow from financing activities?
The current annual CFF of ALGS is $88.33 M
What is the all time high annual CFF for Aligos Therapeutics?
Aligos Therapeutics all-time high annual cash flow from financing activities is $192.35 M
What is Aligos Therapeutics annual CFF year-on-year change?
Over the past year, ALGS annual cash flow from financing activities has changed by +$88.16 M (+53758.54%)
What is Aligos Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ALGS is -$4000.00
What is the all time high quarterly CFF for Aligos Therapeutics?
Aligos Therapeutics all-time high quarterly cash flow from financing activities is $193.32 M
What is Aligos Therapeutics quarterly CFF year-on-year change?
Over the past year, ALGS quarterly cash flow from financing activities has changed by +$17.00 K (+80.95%)
What is Aligos Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ALGS is $88.19 M
What is the all time high TTM CFF for Aligos Therapeutics?
Aligos Therapeutics all-time high TTM cash flow from financing activities is $271.44 M
What is Aligos Therapeutics TTM CFF year-on-year change?
Over the past year, ALGS TTM cash flow from financing activities has changed by +$87.68 M (+17091.81%)